Procedural Safety and Device Performance of the Portico™ Valve from Experienced TAVI Centers: 30-Day Outcomes in the Multicenter CONFIDENCE Registry

• Published in: Journal of clinical medicine Vol. 11; no. 16; p. 4839
• Main Authors: Mollmann, Helge, Linke, Axel, Nombela-Franco, Luis, Sluka, Martin, Dominguez, Juan Francisco Oteo, Montorfano, Matteo, Kim, Won-Keun, Arnold, Martin, Vasa-Nicotera, Mariuca, Conradi, Lenard, Camuglia, Anthony, Bedogni, Francesco, Manoharan, Ganesh
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 18.08.2022; MDPI
• Subjects: Aortic stenosis; Cardiovascular disease; Clinical medicine; Coronary vessels; FDA approval; Heart; Informed consent; Mortality; Minneapolis Minnesota; United States > US
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11164839

A total of 1001 subjects (82.0 years, 62.5% female, 63.7% NYHA III/IV at baseline) with severe aortic stenosis at high surgical risk were enrolled in the prospective CONFIDENCE registry and treated with a Portico™ transcatheter heart valve (THV) using either a first-generation delivery system (DS) or the FlexNav™ DS. The objective of this registry is to characterize the procedural safety and device performance of the Portico™ THV at 30 days. The study collected ‘standard-of-care’ clinical and device performance data, with adverse events adjudicated by an independent clinical event committee according to the Valve Academic Research Consortium-2 criteria. The implantation of a single Portico™ THV was successful in 97.5% of subjects. The 30-day all-cause mortality, cardiovascular mortality, and disabling stroke rates were 2.6%, 2.1%, and 1.8%, respectively. A new pacemaker was implanted in 19.0% of subjects at 30 days. At 30 days, the effective orifice area and mean gradient values were 1.82 cm2 and 7.1 mmHg, respectively. The 30-day rate of moderate paravalvular leak (PVL) was 2.1%, with no occurrence of severe PVL. The Portico™ THV demonstrated improved hemodynamic performance and low rates of safety events at 30 days in a large cohort of subjects implanted with the Portico™ THV with either the first-generation DS or FlexNav™ DS.